| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Eltroxin | GlaxoSmithkline | Surgipharm Ltd | 0.1mg | 100 | Tablet | per tablet | KES 1,057.70 |
| Thyroxine | Actavis (also see Alpharma) | Kulal International Ltd. | 50mcg | 28 | Tablet | per tablet | KES 90 |
| Thyroxine | Actavis (also see Alpharma) | Kulal International Ltd. | 50mcg | 1000 | Tablet | per tablet | KES 1092 |
| Thyroxine | Actavis (also see Alpharma) | Kulal International Ltd. | 100mcg | 28 | Tablet | per tablet | KES 105 |
| Thyroxine | Actavis (also see Alpharma) | Kulal International Ltd. | 100mcg | 1000 | Tablet | per tablet | KES 1238 |
| Thyroxine | Actavis (also see Alpharma) | Kulal International Ltd. | 25mcg | 28 | Tablet | per tablet | KES 200 |
| Tiroy | Modern Pharma Ltd. | Metro Pharmaceuticals Ltd. | 25mcg | 100 | Tablet | per tablet | KES 180 |
| Tiroy | Modern Pharma Ltd. | Metro Pharmaceuticals Ltd. | 150mcg | 100 | Tablet | per tablet | KES 180 |
| Tiroy | Modern Pharma Ltd. | Metro Pharmaceuticals Ltd. | 100mcg | 100 | Tablet | per tablet | KES 210 |
| L-Thyroxine More info | |
|---|---|
| Mode Of Action | Thyroxine is involved in normal metabolism, growth and development, particularly the development of the central nervous system (CNS) of infants. |
| Drug Indication | Hypothyroidism |
| Precautions | Myocardial and adrenal insufficiency; para-hypopituitarism; diabetes mellitus; diabetes insipidus; pregnancy angd lactation. Pre-therapy ECG is important. |
| Contra-Indications | Thyrotoxicosis |
| Side Effects | Skeletal muscle cramps; palpitation; anginal pain; excess weight loss; insomnia; flushing; GI disturbances; CNS disturbances. |
| Dosage | 50-100mcg daily increasing by 50mcg at 3-4 weeks interval. Maintenance dose: 150mcg - 300mcg daily. |
| Pregnancy Category | Category A1: |
| Pregnancy Category Description | Drugs which have been taken by a sizeable number of pregnant women and women of child-bearing age with no any established rise in the frequency of malformations or other direct or indirect detrimental effects on the foetus having been noted. |
| Drug Category | DRUGS AFFECTING NUTRITION AND METABOLISM |
| Drug Sub-Category | Thyroid hormones |